The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Learning Materials for the K-12 Segment in Spain
![Finland Finland flag](https://www.greenhill.com/sites/default/files/finland.gif)
Advising Sanoma Oyj (HEL: SAA1V), a European learning and media company listed on Nasdaq Helsinki, on the acquisition of Santillana Spain, a leading Spanish provider of K-12 learning materials, from Promotora de Informaciones S.A. (Grupo Prisa, BME: PRS)
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Axión Group
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
Advised AMP Capital on the sale of its portfolio company Axión Group, a leading independent broadcasting and telecommunications infrastructure provider in Spain, to Asterion Industrial Partners, a Spanish infrastructure fund
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Cosmetic applications endolysin
![Netherlands Netherlands flag](https://www.greenhill.com/sites/default/files/niederland.gif)
Advised Micreos, a fast-growing biotechnology company, on a long-term license agreement with L’Oréal for one of Micreos’ phage-based active ingredients, SA.100
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
VX Fiber
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised VX Fiber, an international infrastructure and technology business focused on Fibre-to-the-Home networks, on its sale to the infrastructure fund AMP Capital
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Community Fibre Limited
![USA/Germany U.S.A., Germany flags](https://www.greenhill.com/sites/default/files/usa_germany.gif)
Advised Warburg Pincus LLC and Deutsche Telekom Capital Partners on the acquisition of a majority stake in CommunityFibre Limited, a leading full fibre network infrastructure platform in UK
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
![Denmark Denmark flag](https://www.greenhill.com/sites/default/files/denmark_flag%5B1%5D.gif)
Global collaboration agreement with Genmab A/S
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised AbbVie, Inc, an NYSE-listed global biopharmaceutical company, on a broad collaboration with Genmab A/S, a leading Danish-listed biotechnology company, to jointly develop and commercialise three next-generation bispecific antibody programs
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Centrifuge and processing equipment business of Koki Holdings Co., Ltd.
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Eppendorf AG, a leading family-owned life science company, on the acquisition of the centrifuge and processing equipment business of KKR-owned Koki Holdings Co., Ltd., a manufacturer of power tools and centrifuge and processing equipment
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Global rights (excluding North America) to ThermaCare (United Kingdom)
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Asia and US rights to Physiogel
![South Korea Korea flag](https://www.greenhill.com/sites/default/files/Korea.jpg)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Wildstone
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Wildstone, a leading aggregation and digitalization company for outdoor billboards, on its sale to Digital Colony, whilst contemporaneously acquiring Insite Poster Group
![Sweden Sweden flag](https://www.greenhill.com/sites/default/files/sweden.gif)
Sye business area of Net Insight AB
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Net Insight AB, a global leader in media networks, on the sale of Sye, a market-leading true live “over-the-top” (OTT) technology for low-latency live streaming, to Amazon.com, Inc.
![Spain Spain flag](https://www.greenhill.com/sites/default/files/spain.gif)
FTTH network including 933,000 BU’s
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advising MasMovil, the fourth largest Spanish telecom operator, in the sale of part of its fibre-to-the-home (FTTH) network to an international infrastructure fund. The transaction perimeter includes 933,000 homes across 5 main Spanish cities
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Starpharma Holdings Limited, patented VivaGel BV® product
![Italy, USA flags](https://www.greenhill.com/sites/default/files/italian-us-flag.png)
Advised Starpharma Holdings Limited on a US licensing agreement of its patented VivaGel BV® product with ITF Pharma, a US subsidiary of Italfarmaco S.p.A., a privately held European specialty pharmaceutical company
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Assets owned by GlaxoSmithKline plc
![](https://www.greenhill.com/sites/default/files/uk_india_flags.png)
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Montserrat Day Hospital Group
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised ASX-listed Primary Health Care, one of Australia’s leading providers of multi-disciplinary healthcare services, on its acquisition of the Montserrat Day Hospital Group, an owner and operator of day hospital facilities
![Spain, France flags](https://www.greenhill.com/sites/default/files/spain-france-flags.png)
IslaLink
![Canada Canada flag](https://www.greenhill.com/sites/default/files/canada.gif)
Advised EQT, a leading alternative investments firm with more than EUR 37 billion of AUM on the sale of its portfolio company IslaLink, a leading neutral and independent submarine fiber infrastructure operator in the Balearic Islands
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
MorphoSys AG
![China China flag](https://www.greenhill.com/sites/default/files/china.gif)
Advised MorphoSys AG, a German biopharmaceutical company, on a regional licensing agreement covering Greater China and comprising its investigational anti-CD38 antibody MOR202 targeting multiple myeloma, with I-Mab
![South Africa/Switzerland South Africa, Switzerland flags](https://www.greenhill.com/sites/default/files/s-africa_switz_91006.gif)
Hirslanden Private Hospital Group
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of generic marketed products in France from Teva Pharmaceutical Industries Ltd.
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of generic marketed products in France to Arrow Generiques SAS (a subsidiary of Aurobindo Pharma Limited).
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Bionomics Limited
![flag not available](https://www.greenhill.com/sites/default/files/n_a_flag.gif)
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
US rights to 37 approved and 5 pipeline generic products
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 42 generic products